Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 Mg/M2, days 1-5) every 4 weeks for eight cycles. Four children under 2 years old were at first treated with eight cycles of ICE chemotherapy, and then irradiated. The ICE regimen was well tolerated by all children, with no irreversible adverse effects. However, dose reductions during the eight cycles were inevitable mainly due to myelosuppression.
Introduction
According to the Brain Tumor Registry of Japan, the 5-year survival rate of the 628 medulloblastoma patients treated between 1969 and 1983 was 26.7%, and 31.2% in patients treated between 1979 and 1983.5) Most patients were treated by surgery and radiation therapy without chemotherapy.
In con trast, a series of 532 medulloblastoma patients treat ed between 1973 and 1986 in the United States achieved an overall 5-year survival rate of 45%. 19) Published series of patients in Western countries have shown higher 5-year disease-free survival rates ranging between 50% and 70% in patients treated with radiotherapy alone since 1975. '17,21) No recent reports concerning this issue from a single institute or a cooperative group have been published in Japan over the past decade. The major problems currently associated with management of medulloblastoma are the high death rate and late morbidity of craniospinal radiother apy. 1,8,9,11,21) Chemotherapy may have a role for at least some and possibly all children with medulloblasto ma.17,18,21) An 81 % disease-free survival rate with a mean observation period of 6 years") and a 5-year survival rate of 82-85%17,18) were achieved using chemotherapy, which should be continued for ap proximately 1 or 2 years. Different drug combina tions, with or without cisplatin, are presently being used before or after radiation therapy.') A 5-year sur vival rate of over 80% has been achieved by eight cy cles of adjuvant chemotherapy given over approxi mately 1 year in a large series of children.l')
We describe the use of the ICE regimen consisting of ifosfamide, cisplatin, and etoposide for the treat ment of pediatric medulloblastoma/posterior fossa primitive neuroectodermal tumor (PNET), the prima ry effects of the ICE regimen, and preliminary fol low-up data.
Clinical

Materials and Methods
This study included 10 children aged 1 to 12 years treated at Hokkaido University Hospital with newly diagnosed medulloblastoma/PNET located in the posterior fossa beginning in 1992. Risk factors such as detailed histological findings and extent of disease were not considered. The parents or guardians had to give informed consent prior to surgery and again prior to ICE chemotherapy. All patients underwent whole neuraxis magnetic resonance (MR) imaging study with and without gadolinium (Gd) enhancement before and after sur gery to assess the extent of disease. Spinal MR imag ing with Gd enhancement was used in all patients to assess tumor dissemination instead of cerebrospinal fluid examination. Total surgical resections were at tempted in patients with Chang's stage T1, T2, or T3a without gross metastasis on MR images (stage Mo or M1).4) Brainstem origin tumors were biopsied or par tially removed.
Ventriculostomy, but not ven triculoperitoneal shunting, was performed at tumor removal in patients with hydrocephalus.
I. Postsurgical adjuvant therapy
Patients received a uniform adjuvant therapy con sisting of eight courses of ICE chemotherapy and craniospinal radiation therapy with a generous local boost to the tumor site. Briefly, the ICE chemother apy regimen was began, if possible, within 2 weeks of the initial diagnostic surgery. All patients had to be given at least one course of the chemotherapy, then received craniospinal radiotherapy with local boost. The ICE regimen was suspended during radiotherapy.
After the recovery of myelosuppres sion caused by craniospinal irradiation, the remain ing cycles of ICE therapy were given. However, children under 2 years old initially received all eight courses of ICE chemotherapy to avoid radiation in jury to their immature central nervous systems. On reaching the age of 2 years, radiotherapy was be gun. The ICE regimen consisted of three agents, ifos famide at 900 mg/m2 (days 1-5), cisplatin at 20 Mg/M2 (days 1-5), and etoposide at 60 mg/m2 (days 1-5) every 4 weeks. Eight 4-week cycles were planned. MR imaging with Gd enhancement was per formed approximately every 4 weeks during each in terval of ICE chemotherapy. To prevent hemorrhag ic cystitis and suppress emesis, sodium 2-mercap toethane sulfonate (810 mg/m2/day) and granisetron hydrochloride (40 or 80 mg/kg/day), a 5-hydroxy tryptamine receptor antagonist, were intravenous ly administered from day 1 through day 5. Hydra tion including infusion of mannitol was done rou tinely.
Patients between 2 and 5 years of age were initially given reduced-dose craniospinal irradiation of 18 Gy plus a local tumor boost of 30-32 Gy. Patients aged 6 years or older received 24 Gy craniospinal irradia tion with a local boost of 30 Gy. The area of spinal or cranial metastatic disease received a local boost up to a total dose of 40 or 45 Gy, respectively. Patients received the craniospinal portion of irradiation first, followed by the local tumor boost. Daily fractions of 2 Gy, 4 days a week, were used. However, patients between 2 and 2.5 years of age received the local boost first to further delay the craniospinal irradia tion.
II. Toxicity-related dose adjustment for ICE regi men All patients underwent urological and audiological examination and renal monitoring before each cycle of chemotherapy.
The chemotherapy doses were modified if there was any evidence of hematological, renal, or audiological toxicity according to the dose reduction criteria described below.
Pure tone audiometry and creatine clearance were examined to monitor the cisplatin toxicity. Distor tion product otoacoustic emission was used for younger children. The cisplatin dosage was reduced to 15 mg/m2/day if hearing loss was greater than 40 dB in the 4000 to 8000-Hz range. The cisplatin dos age was reduced to 10 mg/m2/day if there was a 20 dB hearing loss in the 50 to 2000-Hz range. If hearing loss was greater than 20 dB in the 50 to 2000-Hz range or if creatine clearance was lower than 70%, the cisplatin was omitted for that cycle and only given thereafter if renal or hearing func tion improved.
Routine urological examination was performed from day 1 to day 5 in each cycle. Ifosfamide was omitted if macrohematuria was observed for at least one dose and begun again when microscopic hematuria disappeared.
The etoposide and ifosfamide dosages were reduced according to an arbitrary score of myelosup pression (Tables 1 and 2 ). These scores were cumula tive over all courses. For example, when the cumula tive score was 7, the dose of etoposide was reduced to 60% and ifosfamide was omitted in the following chemotherapy course. 
Results
I. Preliminary clinical results
Eight of 10 children underwent either gross total or subtotal surgical resection (Table 3) . Two brain stem tumors were biopsied (Case 5, stage T4M0) or partially removed (Case 8, stage T3bM3).
Seven of 10 patients began ICE chemotherapy within 2 weeks of initial diagnostic surgery. The other three underwent surgery at our affiliated hos pitals and began chemotherapy later. Only Case 10 did not receive chemotherapy before radiotherapy. Eight of 10 patients received a total of eight courses of ICE therapy. In Case 5, the fourth course of ICE therapy was interrupted due to tumor pro gression. In Case 10, the patient refused the seventh course of chemotherapy.
Total radiation doses given to individual patients are listed in Table 3 . Case 1 did not receive the craniospinal radiotherapy because of hesitation by her parents.
Nine of 10 children achieved a complete remission defined as tumor disappearance on MR images at least once during the chemotherapy. However, Case 4 recurred immediately after the radiation therapy. Therefore, the primary response rate evaluated at 1 months after completion of the combined chemoradi ation therapy was 80% (8/10) ( Table 4) . Six of seven patients who underwent gross total removal of their tumor successfully maintained their tumor-free sta tus. Case 2 who underwent subtotal removal achieved complete remission after only preradiation ICE chemotherapy. Case 8 who had serious subarachnoid dissemination ( Fig. 1 ) had complete remission after three courses of preradiation ICE therapy (Fig. 2) . At the final follow-up, two patients had died and eight patients were still alive. Seven patients were free of progressive disease, but one child was alive with recurrent tumor. The disease-free survival rate was 70% (7/10) at a mean follow-up period from sur gery of 24 months.
Treatment failure occurred in three patients. Case 1 recurred with subarachnoid dissemination 21 months after surgery (Table 4) . This patient had not received craniospinal radiation therapy when aged 2 years. Case 4 died of progressive disease 14 months after surgery. This 1.5-year-old boy underwent a gross total removal of a large midline cerebellar tumor and then received eight courses of ICE ther apy. Although MR images at the beginning of radia tion therapy demonstrated complete disappearance of the tumor, the medulloblastoma recurred at the primary site with subarachnoid seeding soon after craniospinal irradiation. Therefore, this case was evaluated as progressive disease, despite the com plete remission for 11 months maintained after sur gery with chemotherapy alone. Case 5, a 2-year-old girl, died of progressive disease 12 months after biopsy. Her tumor was mainly situated in the pons ex tending to the right cerebellum and exophytically into the cerebellopontine cistern. The tumor includ ed gross calcification on computed tomography (CT) scans. Histological examination of the biopsy speci men showed small, round cells with Homer-Wright rosettes consistent with a diagnosis of classical medul loblastoma or posterior fossa PNET.
II. Toxicity of ICE regimen A total of 73 courses of ICE chemotherapy were given to 10 children. The ICE regimen was well toler ated, with no irreversible adverse effects. There was no severe ototoxicity, hematuria, or nephrotoxicity. However, dose reductions of the agents during the eight cycles were essential in all patients, mainly due to myelosuppression.
The mean nadir of the white blood cell counts, granulocyte (with bands) counts, platelet counts, and hemoglobin were 1490 ± 601 (SD)/,ul, 535 ± 259/,ul, and 79,427.1 x 104 ± 36,391/,1, respectively. Administration of recom binant granulocyte-colony stimulating factor was needed during almost every course of ICE therapy in all patients. An average of two red blood cell transfu sions per patient were required due to mild anemia, when the hemoglobin level fell below 10 g/dl.
Case 3 developed severe granulocytopenic fever with painful stomatitis, resulting in a 3-week delay to the next chemotherapy.
Otherwise, there were no life-threatening infections. Case 2 had nasal bleeding with thrombocytopenia (platelet count 7000/,ul) and received a platelet transfusion.
Cisplatin ototoxicity was not severe. Mild high tone hearing loss, greater than 40 dB in the 4000 to 8000-Hz range, was recorded in only two patients. Reduction of the cisplatin dose enabled full-dose ad ministration in the following courses. Creatine clear ance was not lower than 70% and no remarkable renal dysfunction was evident in any patient.
Macroscopic hematuria occurred in Case 9 on 1 day during the third course, but did not recur in later courses. Microscopic hematuria was found only in four courses (3 patients) and did not require reduc tion in the ifosfamide dose.
Discussion
This pilot study achieved a primary response rate at 1 month after completion of the chemoradiation ther apy of 80% (8/10), and the disease-free survival rate was 70% (7/10) with a mean observation period of 24 months after surgery, suggesting that the ICE regi men is at least feasible for children with medullo blastoma. In addition, ICE chemotherapy may be useful for pre-irradiation chemotherapy in younger children.
The treatment failed in three patients. The tumor in Case 5 was a peculiar type which was totally resistant to both chemotherapy and high-dose irradia tion. The histological findings of the biopsy were con sistent with medulloblastoma, but other types of ne oplasms, such as malignant rhabdoid tumor or high grade astrocytic tumors may have been present, espe cially malignant rhabdoid tumor which is known to be resistant to chemoradiation therapy and has a similar CT and MR imaging appearance to PNET.3,10>
Chemotherapy currently has a definite role in the management of children with medulloblastoma.17) It has been shown that either cisplatin or etoposide sin gle agent chemotherapy can achieve partial or com plete response in recurrent medulloblastomas.2, 13, 20) Cyclophosphamide has been also used in combina tion therapy of medulloblastomas.1, 14) Cisplatin, etoposide, and cyclophosphamide are active agents against medulloblastoma.1-3,13, 14,1',18,20,21) Ifosfamide is a derivative of cyclophosphamide, with a similar spectrum of antitumor activity. The choice of the ICE regimen used in our pilot trial was based on the information available in 1991.18) We used the ICE regimen for pre and post-irradia tion chemotherapy.
This "sandwich" chemotherapy has already shown promising results, post-surgery and pre-irradiation, using various chemotherapeutic agents. l,7-9,11-13,15-1'> This approach exploits the period of minimal tumor burden after debulking surgery, when the residual tumor, theoretically, has maximal blood supply.') Furthermore, reduction of the tumor volume by pre-irradiation chemotherapy may en hance the effect of subsequent irradiation. Preradia tion chemotherapy can also be used to delay irradia tion of the developing brain in younger children.'°9) In our series, the tumors in four children under the age of 2 years were successfully controlled with ICE therapy alone. Based on this result, we recently modified the protocol described in this report so that children less than 2.5 years of age are treated with ICE chemotherapy alone.
The intrinsic risk of pre-irradiation chemotherapy is that chemotherapy may simply delay radiotherapy, so reducing the radiological impact of this effective treatment.0 Although Case 4 suffered early recur rence just after craniospinal irradiation, we recom mend this approach to reduce post-treatment sequelae, in particular the cognitive dysfunction of younger children. 11)
In the United States and Europe, progress in the treatment of childhood malignancies has been ex pedited through the cooperative group mechanism, in which multiple institutions contribute patients for prospective randomized clinical trials.) Compared to the adult population with cancer, a much larger proportion of children are treated in specialized cen ters and enter prospective clinical trials. Therefore, of all the common childhood brain tumors, the greatest improvement in prognosis has occurred with medulloblastoma.
Unfortunately, there has been neither centralization nor specialization of institutes where children with malignant brain neoplasms are managed in Japan. This system has hampered standardization of therapeutic methods, especially in tensive chemotherapy for a long period. Further evo lution of the management for children with medul loblastoma cannot be achieved in Japan without specialization of certain neurosurgical institutes for pediatric neurooncology. This article is significant for readers desiring to ac quaint themselves with the latest trend in chemotherapy for medulloblastoma/posterior fossa primitive neuroectodermal tumors (MB/PNET) patients. Recently I treated a 5-year-old girl with recurrent MB, who suffered local recurrence of the tumor associated with diffuse disseminations into the intracranial and intraspinal subarachnoid spaces, and I found that the IEC chemotherapy regi men devised by the authors was dramatically effec tive, with transient disappearance over a period of 3 months of tumors defined by neuroimaging which had been refractory to other chemotherapeutic regi mens. I congratulate the authors on their newly devised chemotherapy for MB/PNET. As the authors comment, it has become apparent that a type of tumor common among infants aged 2 which generally has been categorized as being wi thin the MB/PNET group belongs in a separate group. This tumor has been called an atypical tera toid/rhabdoid tumor (ATT/RhT) because either all or a portion of the tumor consists of rhabdoid cells. It was reported to be refractory to chemotherapeu tic regimens usually effective for MB/PNET. The tumors in Cases 4 and 5 resistant to the IEC chemotherapy regimen also would have been categorized as ATT/RhT if the authors had exam ined them electron microscopically as well as histo logically. In the future, multidisciplinary investiga tions should be conducted to elucidate why por tions of tumors traditionally categorized within a group should be refractory to treatment.
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